FDA briefing docs for 10/17/11 panel on Teva’s Azilect: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM275474.pdf http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/ucm235850.htm Teva is trying to get an expanded label for “disease modification” in Parkinson’s.